廣告
香港股市 已收市

  • 恒指

    17,284.54
    +83.27 (+0.48%)
     

  • 國指

    6,120.37
    +20.15 (+0.33%)
     

  • 上證綜指

    3,052.90
    +8.08 (+0.27%)
     

  • 道指

    38,460.92
    -42.77 (-0.11%)
     

  • 標普 500

    5,071.63
    +1.08 (+0.02%)
     

  • 納指

    15,712.75
    +16.11 (+0.10%)
     

  • Vix指數

    16.61
    +0.64 (+4.07%)
     

  • 富時100

    8,099.14
    +58.76 (+0.73%)
     

  • 紐約期油

    83.18
    +0.37 (+0.45%)
     

  • 金價

    2,338.40
    0.00 (0.00%)
     

  • 美元

    7.8287
    -0.0022 (-0.03%)
     

  • 人民幣

    0.9250
    +0.0003 (+0.03%)
     

  • 日圓

    0.0501
    -0.0001 (-0.30%)
     

  • 歐元

    8.3696
    -0.0061 (-0.07%)
     

  • Bitcoin

    63,731.97
    -2,772.44 (-4.17%)
     

  • CMC Crypto 200

    1,362.19
    -20.38 (-1.47%)
     

Treace Medical Shares Interim Data From Corrective Toe Surgery Trial

Vandana Singh
·1 分鐘文章

  • Treace Medical Concepts Inc (NASDAQ: TMCI) announced an audio poster presentation of the latest interim analysis from the ALIGN3D clinical study following the Lapiplasty Procedure for surgical treatment of hallux valgus (bunions).

  • The data showed:

    • Early return to weight bearing in a walking boot at an average of 8.3 days.

    • A low recurrence rate, defined as loss of radiographic correction, was observed in 1.4% of patients (2 out of 144).

    • An 81% reduction in pain (Visual Analog Scale) was reported at 24 months post-procedure (n=107).

  • The interim analysis also continued to report statistically significant improvement in Patient-Reported Outcomes.

  • At 24 months post-surgery (n=107), an 82% and 84% improvement was observed in walking/standing and social interaction, respectively.

  • Further, statistically significant improvements in physical, mental, and social health scores were reported.

  • Price Action: TMCI shares closed 4.37% lower at $23.33 on Tuesday.

See more from Benzinga

廣告

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.